UPDATE: Feltl & Co Upgrades DexCom from Hold to Buy and Lowers PT from $15.85 to $15.35

Feltl and Company has published a research report on DexCom Inc.

upgrading the company. In the report, Feltl & Company wrote, "The recent market correction has seen DexCom sell off to near its 52-week low. This has lowered the company's enterprise value to ~$650 million or about 3.8x our 2013 revenue estimate. We believe the current share price offers a favorable risk-reward trade-off, especially for a company growing at over 40% and rapidly approaching profitability." Feltl & Company upgraded DexCom from Hold to BUY with a price target lowered from $15.85 to $15.35. DexCom closed Monday at $11.54.